MedPlus Q2 FY27 Results: Revenue and Margin Focus

Results are due on October 27

MedPlus Health Services is scheduled to announce its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company’s board is due to meet on October 27, 2026, to consider and approve the numbers. Investors will focus on whether revenue growth has remained strong after the June quarter and whether profitability has improved from the levels that disappointed the market after Q1 FY27. The trading window has been closed from October 1 until 48 hours after the results declaration. MedPlus has said the results will be available on its website and on the websites of BSE and NSE.

Revenue expectations point to continued growth

Consensus expectations cited ahead of the result place Q2 FY27 revenue at about ₹1,920 crore. That would be broadly consistent with a 15% year-on-year growth trajectory. The expected figure follows reported revenue of ₹1,880 crore in the June 2026 quarter, when revenue increased 21.8% from ₹1,543 crore a year earlier. Revenue growth remains central to the company’s investment case because MedPlus is expanding its pharmacy retail network while operating in a competitive, scale-driven market. The Q2 release will indicate whether the pace of growth has held through the September quarter.

Margins are the central issue for investors

The larger question is whether operating margins move back towards the 8% to 9% range seen through most of the past five quarters. MedPlus reported healthy sales growth in Q1 FY27, but profitability was weaker than investors expected. The company reported net profit of ₹33.0 crore for the June 2026 quarter, down 21.4% from ₹42.0 crore in the corresponding quarter a year earlier. This contrast between rising revenue and lower profit put greater attention on costs, product mix and operating leverage. The Q2 numbers will therefore be assessed not only for sales growth but also for evidence of margin stabilisation.

Private-label mix is a stated lever

Management has identified private-label growth as one route to margin recovery. It has targeted an increase of 0.3 to 0.5 percentage points in private-label share per quarter. A higher private-label mix can be relevant to gross margins because it changes the product composition of pharmacy sales. The September-quarter result may provide an update on the execution of this strategy. However, the supplied information does not provide a private-label share figure for Q2 FY27. Investors will therefore look for management commentary alongside the reported financial data.

Store additions will test scale benefits

MedPlus has guided for 800 net store additions in FY27, including franchise stores. The plan is significant because a larger network can support revenue growth and potentially create operating leverage over time. At the same time, rapid additions can require upfront spending and can affect near-term profitability. MedPlus was described as India’s second-largest pharmacy retailer, with 4,930 stores across 13 states and one union territory, serving 750 cities as of Q2 FY26. The results call may offer information on the pace of additions during the first half of FY27.

June-quarter performance sets the comparison base

For the quarter ended June 30, 2026, MedPlus reported revenue of ₹1,880 crore and net profit of ₹33.0 crore. Earnings per share were ₹2.76. Separately, the quarterly financial table lists total income of ₹1,899.43 crore for June 2026, compared with ₹1,557.65 crore in June 2025. Total income is not necessarily the same measure as revenue from operations, so the two figures should be considered separately. The table also shows profit and loss for the year of ₹33.17 crore for June 2026, versus ₹42.34 crore a year earlier.

Key figures to watch

Market reaction will hinge on profitability

MedPlus shares had declined after the company’s Q1 FY27 result, despite revenue growth of about 21.9%, because the profitability outcome was seen as weaker than expected. That reaction underscores the importance of the Q2 margin trend. Revenue expansion alone may not settle investor concerns if net profit and operating metrics do not show improvement. Conversely, the result could provide a clearer picture of whether private-label expansion and a growing store base are contributing to the margin recovery indicated by management. The reported figures and management commentary will be more important than expectations alone.

Prior quarterly data shows a higher profit base

The quarterly table shows profit and loss of ₹63.97 crore in March 2026, ₹57.75 crore in December 2025 and ₹55.50 crore in September 2025. Total income in those quarters was ₹1,884.98 crore, ₹1,824.36 crore and ₹1,696.80 crore, respectively. The June 2026 profit of ₹33.17 crore was therefore lower than the preceding three quarters despite total income reaching ₹1,899.43 crore. This sequence explains why the September-quarter margin outcome is receiving close attention. It will help establish whether the June-quarter decline was temporary or part of a broader pressure on profitability.

Earnings call follows on October 28

MedPlus is scheduled to hold its Q2 FY27 earnings call on October 28, 2026, at 4:00 PM IST. The call is expected to be the next formal opportunity for management to discuss revenue, margins, store additions and private-label progress after the board approves the results. The immediate focus will be on the September-quarter financial statements and the company’s stated FY27 expansion plan. Investors will also await any confirmed update on the pace of store additions and the margin outlook. Until then, the expected ₹1,920 crore revenue figure and the 8% to 9% operating-margin reference remain the key benchmarks for the Q2 FY27 announcement.